Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
GSGMm0NzqJ00Ths9
Listen
